+ Site Statistics
References:
52,572,879
Abstracts:
28,705,754
PMIDs:
27,750,366
DOIs:
25,464,004
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Three months of octreotide treatment decreases gastric acid secretion and argyrophil cell density in patients with Zollinger-Ellison syndrome and antral G-cell hyperfunction



Three months of octreotide treatment decreases gastric acid secretion and argyrophil cell density in patients with Zollinger-Ellison syndrome and antral G-cell hyperfunction



Alimentary Pharmacology & Therapeutics 8(1): 95-104



Methods: The effects of three months of treatment with octreotide on gastric acid hypersecretion induced by hypergastrinaemia were investigated in patients with Zollinger-Ellison syndrome (n = 5) or antral G-cell hyperfunction (n = 4). Gastric acid secretion, fasting plasma gastrin concentrations and clinical findings were examined, and a morphometrical analysis of oxyntic endocrine cells was performed. Results: Administration of octreotide 100 mcg b.d. subcutaneously significantly decreased the volume density of argyrophil cells (P lt 0.05) as well as basal and pentagastrin-stimulated acid secretion (P lt 0.05). Although partial or complete loss of inhibition was found in most patients after 3 months, gastrin levels were decreased during the first 2 months of treatment (P lt 0.05). Fundic D-cells were not affected by treatment. Positive correlations were observed between volume density of argyrophil cells and basal acid output (r = 0.65); plasma gastrin and basal acid output (r = 0.74); plasma gastrin concentrations and volume density of argyrophil cells (r = 0.80). Conclusion: These results support the important role of the enterochromaffin-like cell in maintaining acid secretion, and indicate a specific role for octreotide in the therapy of gastric acid hypersecretion associated with hypergastrinaemic diseases.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 009644396

Download citation: RISBibTeXText

PMID: 7910489

DOI: 10.1111/j.1365-2036.1994.tb00165.x


Related references

Zollinger-Ellison syndrome and antral G-cell hyperfunction in patients with resistant duodenal ulcer disease. Alimentary Pharmacology & Therapeutics 8(1): 87-93, 1994

Gastric endocrine cell proliferation and fundic argyrophil carcinoid tumors in patients with the Zollinger-Ellison syndrome. Acta Oncologica 32(2): 135-140, 1993

Differential effects of somatostatin analog sms 201 995 on g and parietal cells function in zollinger ellison syndrome zes and antral g cell hyperfunction agch. Gastroenterology 100(5 PART 2): A26, 1991

Parietal cell mass and gastric acid secretion in the Zollinger-Ellison syndrome. Surgery 60(3): 606-614, 1966

Parietal cell mass and gastric acid secretion in the zollinger ellison syndrome human histamine gastro intest. Surgery (St Louis) 60(3): 606-614, 1966

Argyrophil cell proliferation in zollinger ellison syndrome. Gastroenterologie Clinique et Biologique 15(5 PART A): 41C-46C, 1991

Long term octreotide treatment of gastric carcinoid tumors in two patients with Zollinger-Ellison syndrome associated with multiple endocrine neoplasia type I. Gastroenterology 108(4 SUPPL ): A966, 1995

Anomalies of fundic argyrophil cell proliferation (enterochromaffin-like cells) in Zollinger-Ellison syndrome. Gastroenterologie Clinique et Biologique 15(5 ): 41c-46c, 1991

Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized association. American Journal of Surgical Pathology 14(6): 503-513, 1990

Delayed recovery of gastric acid secretion after prolonged omeprazole omp treatment in zollinger ellison syndrome zes. Gastroenterology 96(5 PART 2): A101, 1989

Gastric argyrophil carcinoid tumors in a case of zollinger ellison syndrome with primary hyperparathyroidism developing during long term antisecretory treatment. Gastroenterology 90(5 PART 2): 1552, 1986

Development of gastric argyrophil carcinoid tumors in a case of Zollinger-Ellison syndrome with primary hyperparathyroidism during long-term antisecretory treatment. Cancer 59(11): 1959-1962, 1987

Argyrophil cell hyperplasia and a carcinoid tumour in the stomach of a patient with sporadic Zollinger-Ellison syndrome. Gut 35(2): 275-277, 1994